Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Coons

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Journal of Clinical Pharmacology|May 13, 2023
DOAC Dosing Discordance Using Different Estimates of Kidney Function and OutcomesNauka J Bhalodia, Evan M White, Archita Achanta, et al.
The Annals of Pharmacotherapy|April 4, 2024
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support SystemElizabeth M Foster, James C Coons, Elena A Puccio, et al.
Journal of Clinical Medicine|June 27, 2024
Post-Discharge Treatment Patterns among Patients Treated with Apixaban or Warfarin during Hospitalization for Venous Thromboembolism (VTE)James C Coons, Vamshi Ruthwik Anupindi, Riddhi Doshi, et al.
Plos One|April 17, 2025
Oral anticoagulant use among Medicare patients newly diagnosed with venous thromboembolism (VTE): Factors associated with treatment statusJames C Coons, Aolin Wang, Dominick Latremouille-Viau, et al.
American Journal of Hematology|June 28, 2019
Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin timeJames C Coons, Carlo J Iasella, Megan Thornberg, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 18, 2025
Outcomes Associated with Time in Therapeutic Range for Patients Receiving Intravenous Unfractionated HeparinMujtaba Mahmud, Maia Klimatcheva, Angela Tsang, et al.
Journal of the American College of Clinical Pharmacy : JACCP|June 6, 2026
Value of Inpatient Clinical PharmacistsZack Dumont, Kelly C Rogers, Abdullah M Alhammad, et al.
The Annals of Pharmacotherapy|April 26, 2017
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery SystemJames C Coons, Carlo J Iasella, Tyler Chanas, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 29, 2019
Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi methodZachary R Smith, Krishna Rangarajan, Jennifer Barrow, et al.
Journal of the American College of Clinical Pharmacy : JACCP|September 28, 2020
Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy PracticeJ Kevin Hicks, Christina L Aquilante, Henry M Dunnenberger, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacology|May 13, 2023
DOAC Dosing Discordance Using Different Estimates of Kidney Function and OutcomesNauka J Bhalodia, Evan M White, Archita Achanta, et al.
The Annals of Pharmacotherapy|April 4, 2024
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support SystemElizabeth M Foster, James C Coons, Elena A Puccio, et al.
Journal of Clinical Medicine|June 27, 2024
Post-Discharge Treatment Patterns among Patients Treated with Apixaban or Warfarin during Hospitalization for Venous Thromboembolism (VTE)James C Coons, Vamshi Ruthwik Anupindi, Riddhi Doshi, et al.
Plos One|April 17, 2025
Oral anticoagulant use among Medicare patients newly diagnosed with venous thromboembolism (VTE): Factors associated with treatment statusJames C Coons, Aolin Wang, Dominick Latremouille-Viau, et al.
American Journal of Hematology|June 28, 2019
Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin timeJames C Coons, Carlo J Iasella, Megan Thornberg, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 18, 2025
Outcomes Associated with Time in Therapeutic Range for Patients Receiving Intravenous Unfractionated HeparinMujtaba Mahmud, Maia Klimatcheva, Angela Tsang, et al.
Journal of the American College of Clinical Pharmacy : JACCP|June 6, 2026
Value of Inpatient Clinical PharmacistsZack Dumont, Kelly C Rogers, Abdullah M Alhammad, et al.
The Annals of Pharmacotherapy|April 26, 2017
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery SystemJames C Coons, Carlo J Iasella, Tyler Chanas, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 29, 2019
Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi methodZachary R Smith, Krishna Rangarajan, Jennifer Barrow, et al.
Journal of the American College of Clinical Pharmacy : JACCP|September 28, 2020
Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy PracticeJ Kevin Hicks, Christina L Aquilante, Henry M Dunnenberger, et al.
Pageof 8